Regeneron Pharmaceuticals Inc

Regeneron’s analyst downgrade signals looming biosimilar pressure, yet the company’s Alvotech‑Teva licensing deal for an Eylea biosimilar may boost revenue, lower costs, and secure market share by Q4 2026.

Regeneron’s upcoming investor conferences reveal new Dupixent data, expanded approvals, and strategic plans—key insights for analysts and healthcare investors.

Regeneron Pharmaceuticals has announced positive results from two Phase 3 clinical trials, one for a novel obesity treatment and the other for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder, marking significant milestones in th…

Regeneron Pharmaceuticals Inc has announced significant advancements in its oncology portfolio, including positive five-year follow-up data for its Libtayo treatment in advanced non-small cell lung cancer, and a definitive settlement with Sandoz to …

Regeneron Pharmaceuticals has made significant breakthroughs in treating rare diseases, including a promising new therapy for generalized myasthenia gravis and a RNA drug for a rare autoimmune disease, with positive trial data expected to lead to FD…

Regeneron Pharmaceuticals has announced a groundbreaking success in its Phase 3 trial for Generalized Myasthenia Gravis, leading to a surge in stock price and market capitalization.

Regeneron Pharmaceuticals Inc is poised for continued growth, driven by its innovative pipeline and strong track record of delivering results, with analysts maintaining or initiating buy ratings and price targets exceeding the current market value.

Regeneron Pharmaceuticals faces challenges in the pharmaceutical industry, including a lowered stock price target and increased competition, amid a complex and evolving market landscape.

Regeneron Pharmaceuticals’ stock price target has surged as top analysts raise their estimates due to strong sales of its flagship product Dupixent and a recent dividend declaration.

Regeneron Pharmaceuticals’ stock price target has been significantly boosted by prominent analysts following a strong earnings report, with estimates reaching as high as $695.